


CLAIMS

1. Chelating agent of the general formula:



wherein m is 0 or 1;

X is NR₄ or S;

Y is SR₅, NHR₅ or P(R₅)₂;

15 R₁ and R₃ are the same or different and are selected from H, alkyl or aryl;

R₂ is H, COOH, NHR₆ or (CH₂)_nCOOR₆;

R₄ is H, alkyl, aryl, (CH₂)_nCOOR₆ or (CH₂)_nOR₆;

R₅ is H, alkyl, aryl, (CH₂)_nCOOR₆ or (CH₂)_nOR₆

20 R₆ is H, alkyl or aryl;

n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and

when R₁=R₃=CH₃, R₂, R₄ and R₅ are not all three H.

2. Chelating agent as claimed in claim 1, wherein the alkyl is a C₁ alkyl, C₂ alkyl, C₃ alkyl, C₄ alkyl, C₅ alkyl or 25 C₆ alkyl.

3. Chelating agent as claimed in claim 2, wherein the alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl (2-methylpentyl), neohexyl (2,2-30 dimethylbutyl), 3-methylpentyl, 2,3-dimethylbutyl.

4. Chelating agent as claimed in claim 1, wherein the aryl is monocyclic, preferably phenyl or benzyl, or


polycyclic, C₁₀-C₁₈, and optionally substituted with alkyl, carboxy, oxo, amino, alkoxy or aldehyde groups.

5. Chelating agent as claimed in claim 4, wherein aryl is phenyl or benzyl.

5 6. Chelating agent as claimed in claim 1, wherein n is 2, 3, 4, 5 or 6 and preferably 2, 3 or 4.

7. Chelating agent as claimed in claim 1, which agent is a pyrazolyl-polyamine of the general formula:


10



wherein R₁, R₂, R₃, R₄ and R₅ are as defined in claim 1.

8. Chelating agent as claimed in claim 1, which agent is a pyrazolyl-aminothioether of the general formula:


20



wherein R₁, R₂, R₃, R₄ and R₅ are as defined in claim 1.


9. Chelating agent as claimed in claim 1, which agent is a pyrazolyl-polythioether of the general formula:

30




wherein R₁, R₂, R₃, R₄ and R₅ are as defined in claim 1.

10. Chelating agent as claimed in claim 1, which agent is a pyrazolyl-aminophosphine of the general formula:



10 wherein R₁, R₂, R₃, R₄ and R₅ are as defined in claim 1.

11. Chelating agent as claimed in claim 1, which agent is a pyrazolyl-thioetherphosphine of the general formula:



20 wherein R₁, R₂, R₃, R₄ and R₅ are as defined in claim 1.

12. Chelating agent as claimed in claim 1, wherein X and Y are N, R₆ is H, C₁ alkyl, C₂ alkyl, C₃ alkyl, C₄ alkyl, C₅ alkyl or C₆ alkyl, phenyl, benzyl or a biomolecule and R₁, R₂, R₃, R₄ and R₅ are as listed in Table 1.

25 13. Chelating agent as claimed in claim 1, wherein X and Y are S, R₆ is H, C₁ alkyl, C₂ alkyl, C₃ alkyl, C₄ alkyl, C₅ alkyl or C₆ alkyl, phenyl, benzyl or a biomolecule and R₁, R₂, R₃, R₄ and R₅ are as listed in Table 1.

14. Chelating agent as claimed in claim 1, wherein X 30 is N and Y is S, R₆ is H, C₁ alkyl, C₂ alkyl, C₃ alkyl, C₄ alkyl, C₅ alkyl or C₆ alkyl, phenyl, benzyl or a biomolecule and R₁, R₂, R₃, R₄ and R₅ are as listed in Table 1.

15. Chelating agent as claimed in claim 1, wherein X is S and Y is N, R₆ is H, C₁ alkyl, C₂ alkyl, C₃ alkyl, C₄ alkyl, C₅ alkyl or C₆ alkyl, phenyl, benzyl or a biomolecule and R₁, R₂, R₃, R₄ and R₅ are as listed in Table 1.

5 16. Chelating agent as claimed in claim 1, wherein X is S and Y is P(R₅)₂, R₆ is H, C₁ alkyl, C₂ alkyl, C₃ alkyl, C₄ alkyl, C₅ alkyl or C₆ alkyl, phenyl, benzyl or a biomolecule and R₁, R₂, R₃, R₄ and R₅ are as listed in Table 1.

10 17. Chelating agent as claimed in claim 1, wherein X is N and Y is P(R₅)₂, R₆ is H, C₁ alkyl, C₂ alkyl, C₃ alkyl, C₄ alkyl, C₅ alkyl or C₆ alkyl, phenyl, benzyl or a biomolecule and R₁, R₂, R₃, R₄ and R₅ are as listed in Table 1.

18. Chelating agent as claimed in claim 1, wherein R₆ 15 is a biomolecule.

19. Chelating agent as claimed in claim 18, wherein the biomolecule is selected from amino acids, peptides, proteins, oligonucleotides, polynucleotides, sugars.

20. Chelating agent as claimed in claim 19, wherein 20 the biomolecule is selected from the group consisting of antibodies, ligands of tumor receptors.


21. Chelating agent as claimed in claim 19, wherein 25 the biomolecule is selected from the group consisting of CCK, thioglucose, glucosamine, somatostatin, neuropeptides, bombesin, CCK, annexin, interleukins, growth factors, steroid hormones and molecules binding to GPIIb/IIIa receptors.

22. Chelating agent as claimed in claim 19, wherein 30 the biomolecule is selected from the group consisting of glucose, thioglucose, neurotransmitters.


23. Chelating agent as claimed in claim 19, wherein the biomolecule is an inhibitor of the tyrosine kinase

activity, such as benzothiopyranones, anilinophthalimides, quinazolines, pyridopyrimidines and pyrrolopyrimidines.

24. Chelating agent as claimed in claim 1, which agent is a compound of the following formula:




10 25. Chelating agent as claimed
agent is a compound of the following fo_____.



26. Chelating agent as claimed in claim 1, which agent is a compound of the following formula:

20



25

27. Chelating agent as claimed in claim 1, wherein the agent is complexed with a carbonyl moiety of the formula $[M(CO)_3]^+$, wherein M is rhenium (Re), technetium (Tc) or manganese (Mn).

30 28. Chelating agent as claimed in claim 18, wherein the agent is complexed with a carbonyl moiety of the formula $[M(CO)_3]^+$, wherein M is rhenium (Re) or technetium (Tc).

29. Method for the preparation of radiolabeled biomolecules comprising:

- a) contacting a chelating agent as claimed in claim 1 with a carbonyl moiety of the formula $[M(CO)_3]^+$, wherein M 5 is rhenium (Re) or technetium (Tc), under conditions for forming a chelator-carbonyl complex; and
- b) contacting the complex with a biomolecule for obtaining a radiolabeled biomolecule.

30. Kit for performing the method as claimed in claim 10 29, comprising a first vial with the chelating agent of the invention, optionally a first reaction vial for contacting the chelating agent with the carbonyl moiety, a second vial with the biomolecule and optionally a second reaction vial for reacting the biomolecule with the chelator-carbonyl 15 complex obtained in the first step of the reaction.

31.. Method for the preparation of radiolabeled biomolecules comprising:

- a) contacting a chelating agent as claimed in claim 1 with a biomolecule for obtaining a chelator-biomolecule; 20 and
- b) contacting the chelator-biomolecule with a carbonyl moiety of the formula $[M(CO)_3]^+$, wherein M is rhenium (Re) or technetium (Tc), under conditions for forming a radiolabeled biomolecule.

25 32. Kit for performing the method as claimed in claim 31, comprising a first vial with the chelating agent of the invention, optionally a first reaction vial for reacting the chelating agent with the biomolecule, a second vial with the carbonyl moiety and optionally a second reaction vial for 30 reacting the chelator-biomolecule obtained in the first step of the reaction with the carbonyl.

33. Chelating agent as claimed in claim 1 for use in

the preparation of a diagnostic or therapeutic agent for diagnosing or treating tumors.

34. Chelating agent as claimed in claim 27 for use as a diagnostic or therapeutic agent for diagnosing or treating 5 tumors.

35. Use of a chelating agent as claimed in claim 1 for the preparation of a diagnostic or therapeutic agent for diagnosing or treating tumors.